Cellectis Reports Results from Shareholders Meeting Held on June 26, 2025

On June 26, 2025, Cellectis, a clinical-stage biotechnology company specialized in gene-editing technology, conducted a general shareholders meeting at the Biopark auditorium in Paris, where approximately 57% of voting rights were exercised. The meeting resulted in the approval of resolutions 1 through 23, along with resolutions 25 and 26, while resolution 24 was notably rejected, reflecting the board of directors’ recommendations.

A significant outcome of the meeting was the appointment of Mr. André Muller to the company's Board of Directors, effective immediately. Mr. Muller currently serves as the Chief Executive Officer of Idorsia Pharmaceuticals, Ltd., a position he holds until July 1, 2025. His impressive background includes previous roles as Chief Financial Officer at Idorsia and Actelion Pharmaceuticals, as well as various financial positions at Pierre Fabre SA. His expertise is expected to be a valuable asset to Cellectis as it progresses in developing life-saving cell and gene therapies.

The meeting also marked the conclusion of tenures for Mr. Axel-Sven Malkomes and Mr. Pierre Bastid, the latter of whom resigned prior to the meeting. Chairman Jean-Pierre Garnier expressed gratitude for their contributions, which significantly advanced the company's strategic vision.

Cellectis, recognized for its pioneering approach to CAR T immunotherapies and innovative gene-editing platforms, maintains its headquarters in Paris and operations in New York and Raleigh, North Carolina. The company stands out for its comprehensive control over the cell and gene therapy value chain. Additional details regarding the meeting's resolutions and voting results are available on Cellectis’ website.

Cellectis, a clinical-stage biotechnology company specializing in gene-editing, recently held its shareholders meeting in Paris on June 26, 2025. A significant 57% of voting rights were exercised, reflecting investor engagement amid the company’s ongoing developments in CAR T immunotherapies and gene therapies. With the adoption of resolutions 1 through 23 and 25 and 26, the outcome demonstrates a solid backing for the board's strategic direction, although the rejection of resolution 24 could indicate some dissent or concern within shareholder ranks.

The appointment of Mr. André Muller to the Board is a crucial development. His extensive experience in the biotech sector, particularly his leadership at Idorsia Pharmaceuticals, may enhance Cellectis’ strategic vision and operational efficiency as the company navigates the complexities of gene-editing technologies. Investors should view this transition in leadership as a positive step, potentially improving Cellectis’ financial management and innovation trajectory.

Despite a robust governance structure, investors should remain cautious about market volatility and the biotech sector's inherent risks. The ongoing advancements in CAR T-cell therapy, where Cellectis pioneers allogeneic approaches, position the company well in a burgeoning market, but clinical trials' unpredictability remains an ever-present concern. With an end-to-end manufacturing model, Cellectis controls its production processes, giving it a competitive edge that could translate to better margins and faster time-to-market.

In summary, Cellectis appears to be on a promising trajectory, particularly with strategic board changes and a firm grip on its operational processes. However, investors should stay informed about trial results and market trends. Given the volatility in biopharma stocks, those involved should consider maintaining a balanced approach, weighing potential gains against the inherent risks of the sector.